Cerus Announces Deal with Swiss Red Cross for Initial Deployment of INTERCEPT Blood System
Cerus Corporation (NASDAQ: CERS) announced today that it has signed a two-year purchase agreement with two regional Swiss Red Cross Blood Services for deployment of the INTERCEPT Blood System for plasma in Lausanne and Zurich. These two pilot centers supply an estimated 15,000 plasma units annually.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.